|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
9/26/2006 10:43:46 AM
MONTREAL, CANADA AND LILLE, FRANCE -- (MARKET WIRE) -- September 26, 2006 -- Pathogen Removal and Diagnostic Technologies Inc. ("PRDT"), a joint venture between ProMetic Life Sciences Inc. (TSX: PLI) and the American Red Cross, along with PRDT's commercial and manufacturing partner, MacoPharma SA ("MacoPharma"), announced at the British Blood Transfusion Society Meeting, Bournemouth, 21-23rd September, 2006, that their prion capture filter, P-Capt™, targeted initially at reduction of TSE pathogens from red blood cell concentrate, has received European Regulatory Approval (CE mark).
|
|
|
|
|
|
|
|
|
|
|